A systematic review of microbiome-derived biomarkers for early colorectal cancer detection

Zwezerijnen-Jiwa, Florine H; Sivov, Hugo Armand Roberto; Paizs, Petra; Zafeiropoulou, Konstantina

doi:10.1016/j.neo.2022.100868

Cited by 20 publications

(21 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, CRC patients exhibit changes in microbiota and fecal metabolome, indicating potential applications in CRC screening and diagnosis[ 117 ]. A recent systematic review including 28 studies indicated optimal diagnostic performance with a sensitivity of 88% and specificity of 94% for CRC diagnosis[ 118 ]. Fusobacterium nucleatum ( Fn ), Lachnoclostridium gene marker (named as “m 3 ”) and Clostridium hathewayi ( Ch ) are some the most extensively studied microbial markers.…”

Section: Promising Screening Testsmentioning

confidence: 99%

Colorectal cancer screening: A review of current knowledge and progress in research

Lopes,

Martins,

Santos

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, being the third most commonly diagnosed malignancy and the second leading cause of cancer-related deaths globally. Despite the progress in screening, early diagnosis, and treatment, approximately 20%-25% of CRC patients still present with metastatic disease at the time of their initial diagnosis. Furthermore, the burden of disease is still expected to increase, especially in individuals younger than 50 years old, among whom early-onset CRC incidence has been increasing. Screening and early detection are pivotal to improve CRC-related outcomes. It is well established that CRC screening not only reduces incidence, but also decreases deaths from CRC. Diverse screening strategies have proven effective in decreasing both CRC incidence and mortality, though variations in efficacy have been reported across the literature. However, uncertainties persist regarding the optimal screening method, age intervals and periodicity. Moreover, adherence to CRC screening remains globally low. In recent years, emerging technologies, notably artificial intelligence, and non-invasive biomarkers, have been developed to overcome these barriers. However, controversy exists over the actual impact of some of the new discoveries on CRC-related outcomes and how to effectively integrate them into daily practice. In this review, we aim to cover the current evidence surrounding CRC screening. We will further critically assess novel approaches under investigation, in an effort to differentiate promising innovations from mere novelties.

show abstract

Section: Promising Screening Testsmentioning

confidence: 99%

Colorectal cancer screening: A review of current knowledge and progress in research

Lopes,

Martins,

Santos

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…It should be noted that microbial panels using other bacteria, such as Clostridium symbiosum, Parvimonas micra and pks+Escherichia coli may also have potential to screen for and detect recurrence of colorectal neoplasia. 88 For screening participants with an abnormal abundance of pathogenic microbes and negative colonoscopy, we suggest that physicians should offer advice on modification of lifestyle habits that could modulate gut microbiota. These include low animal protein intake, low fat intake and high fibre consumption; weight reduction; and administration of probiotics.…”

Section: Summary Recommendations For Use Of Stool Based Microbial Bio...mentioning

confidence: 99%

“…It may be possible to use microbiome based biomarkers to not only predict the presence of lesions but also to assess the risk of recurrence due to these changes in the microbiota. It should be noted that microbial panels using other bacteria, such as Clostridium symbiosum , Parvimonas micra and pks+ Escherichia coli may also have potential to screen for and detect recurrence of colorectal neoplasia 88…”

Section: Executive Summary Of Key Recommendationsmentioning

confidence: 99%

Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia

Chan

Wong

Chan

et al. 2023

Gut

View full text Add to dashboard Cite

Screening for colorectal cancer (CRC) is effective in reducing CRC related mortality. Current screening methods include endoscopy based and biomarker based approaches. This guideline is a joint official statement of the Asian Pacific Association of Gastroenterology (APAGE) and the Asian Pacific Society of Digestive Endoscopy (APSDE), developed in response to the increasing use of, and accumulating supportive evidence for the role of, non-invasive biomarkers for the diagnosis of CRC and its precursor lesions. A systematic review of 678 publications and a two stage Delphi consensus process involving 16 clinicians in various disciplines was undertaken to develop 32 evidence based and expert opinion based recommendations for the use of faecal immunochemical tests, faecal based tumour biomarkers or microbial biomarkers, and blood based tumour biomarkers for the detection of CRC and adenoma. Comprehensive up-to-date guidance is provided on indications, patient selection and strengths and limitations of each screening tool. Future research to inform clinical applications are discussed alongside objective measurement of research priorities. This joint APAGE–APSDE practice guideline is intended to provide an up-to-date guide to assist clinicians worldwide in utilising non-invasive biomarkers for CRC screening; it has particular salience for clinicians in the Asia-Pacific region.

show abstract

“…Ein Verlust der mikrobiellen Diversität sowie Veränderungen in der quantitativen Zusammensetzung des Mikrobioms erlauben eine Differenzierung zwischen gesunden Personen und Patienten mit kolorektalen Karzinomen [28]. Es liegen mittlerweile zahlreiche Studien vor, die untersucht haben, inwieweit eine Analyse des Mikrobioms und des Co-Metaboloms für die Identifikation von Risikopersonen und für die Früherkennung kolorektaler Neoplasien eingesetzt werden können [29]. Unter dem Co-Metabolom wird dabei die Summe der Stoffwechselprodukte von mehr als 1 Genom, die in einem symbiotischen System interagieren, verstanden.…”

Section: Mikrobiommarkerunclassified

Verfahren zur Früherkennung kolorektaler Neoplasien

Kolligs

2023

Gastroenterologie up2date

View full text Add to dashboard Cite

A systematic review of microbiome-derived biomarkers for early colorectal cancer detection

Cited by 20 publications

References 87 publications

Colorectal cancer screening: A review of current knowledge and progress in research

Colorectal cancer screening: A review of current knowledge and progress in research

Joint Asian Pacific Association of Gastroenterology (APAGE)–Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia

Verfahren zur Früherkennung kolorektaler Neoplasien

Contact Info

Product

Resources

About